Touch Medical Media have carefully selected some of the above video content from 3rd party sources for educational & informational purposes and are hosting the content as 'fair use' Under Section 107 of the Copyright Act 1976.
- Clinical Benefit Associated with Participation in Modern Phase I Oncology Studies
- ASCO 2018: Large Study of DNA Mismatch Repair Genes Determines Mutation Frequency in Several Types of Cancer
- FDA Approves Pembrolizumab for Treatment of Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
- FDA Approves Bevacizumab in Combination with Chemotherapy for Ovarian Cancer
- FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy
- 20 Years of Excellence in Gastrointestinal Research and Practice [WCGI Media Alert]
At a press conference at ASCO 2014, Prof Sweeney (Dana-Farber Cancer Institute, Boston, USA) presents the findings that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with hormone-sensitive prostate cancer.
Dr Pérol talks to ecancertv at ASCO 2014 about the findings from the REVEL phase III study of patients with stage IV non-small cell lung cancer (NSCLC)
Prof Zweegman (VU University Medical Center, Amsterdam, Netherlands) and Prof Aapro (Multidisciplinary Oncology Institute, Clinique De Genolier, Switzerland) discuss the latest multiple myeloma data presented at EHA 2014.
Prof Mateos (University Hospital of Salamanca, Salamanca, Spain) and Prof Moreau (Centre Hospitalier Universitaire de Nantes, Nantes, France) discuss multiple myeloma, with a particular focus on elderly patients, for ecancertv at EHA 2014.
Dr Rule (Derriford Hospital, Plymouth, UK) and Prof Cavalli (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) discuss recent data on MCL for ecancertv at EHA 2014.
Prof Gribben (Queen Mary University London, London, UK) chairs a discussion with Prof Hillmen (St James’ University Hospital, Leeds, UK), and Prof Mulligan (Royal North Shore Hospital, St Leonards, Australia) about the advances in CLL.
Prof Sznol at ASCO 2014 about concurrent treatment with immunotherapy drugs ipilimumab and nivolumab produces an unprecedented median survival of roughly three and a half years (40 months) for patients with advanced melanoma.
Dr Salazar talks to ecancertv at ASCO 2014 about how colorectal cancer patients that respond better to treatment without adjuvant chemotherapy can be better identified.
Prof Giagounidis (St. John’s Hospital, Duisburg, Germany) chairs a discussion with Dr Zaja (University of Udine, Udine, Italy), Dr Liebman (University of Southern California, Los Angeles, USA), and Dr Bussel (Cornell University, Ithaca, USA) for ecancertv at EHA 2014 about the latest in ITP treatment options.
Minimally-invasive lung cancer surgery is done through very few small incisions and the recovery process is much easier on the patient and family. Our thoracic surgery team is dedicated to this process.